PRESS RELEASE published on 09/22/2026 at 17:40, 1 month ago VALBIOTIS SA: Valbiotis announces positive results from the Cardio-Liver clinical study - Commercial launch of ValbiotisPRO® Foie on September 23 Valbiotis announces positive results from Cardio-Liver study and commercial launch of ValbiotisPRO® Foie on September 23. Study confirms efficacy of Steadrive® on liver fat reduction Valbiotis Clinical Trial Steadrive® Cardio-Liver Study ValbiotisPRO® Foie
BRIEF published on 09/07/2026 at 17:50, 1 month 15 days ago VALBIOTIS: Update on voting rights and capital Share Capital Voting Rights Euronext Growth Regulation Valbiotis
BRIEF published on 08/17/2026 at 17:45, 2 months 5 days ago VALBIOTIS SA: Update of voting rights and shares as of July 31, 2026 Voting Rights Actions Euronext Growth Threshold Crossing Valbiotis SA
BRIEF published on 07/27/2026 at 17:45, 2 months 26 days ago Valbiotis welcomes the law on cardiovascular prevention Valbiotis Screening Cardiometabolic Health Cardiovascular Prevention Pharmacist
BRIEF published on 07/27/2026 at 17:45, 2 months 26 days ago Valbiotis Applauds Cardiovascular Prevention Legislation Valbiotis Healthcare Strategy French Legislation Cardiometabolic Health Cardiovascular Prevention
PRESS RELEASE published on 07/27/2026 at 17:40, 2 months 26 days ago VALBIOTIS SA: Cardiovascular Prevention Act: A response to a major public health challenge A milestone fully aligned with Valbiotis’ mission Valbiotis welcomes the final adoption of the Cardiovascular Prevention Act by the French Parliament, emphasizing prevention of cardiovascular and neurovascular diseases in France's national strategy Healthcare Valbiotis Prevention Cardiovascular Prevention Act French Parliament
BRIEF published on 07/22/2026 at 17:45, 3 months ago Valbiotis' REVERSE-IT Study Gains International Recognition Diabetes Management TOTUM•63 Nature Communications Cardiometabolic Health REVERSE-IT Study
BRIEF published on 07/22/2026 at 17:45, 3 months ago Publication of the results of the Valbiotis REVERSE-IT study Diabetes Valbiotis Nature Communications REVERSE-IT Total•63
PRESS RELEASE published on 07/22/2026 at 17:40, 3 months ago VALBIOTIS SA: Results of the REVERSE-IT clinical study published in Nature Communications, a major international scientific recognition for the ingredient Totum•63 Results of the REVERSE-IT clinical study published in Nature Communications, showcasing significant benefits of Totum•63 in cardiometabolic health Clinical Study TOTUM•63 Nature Communications Cardiometabolic Health REVERSE-IT
BRIEF published on 07/22/2026 at 09:55, 3 months 1 day ago Half-year review of Valbiotis' liquidity contract Liquidity Transactions Actions PORTZAMPARC Valbiotis
Published on 10/23/2026 at 02:20, 7 hours 42 minutes ago Apex Announces Nasdaq Listing and Pricing of US$1.86 Million Offering
Published on 10/22/2026 at 23:30, 10 hours 32 minutes ago Cypher Announces Subscription Receipt Offering
Published on 10/22/2026 at 22:30, 11 hours 32 minutes ago Unusual Machines to Announce Third Quarter 2026 Financial Results and Provide Corporate Update
Published on 10/22/2026 at 16:00, 18 hours 2 minutes ago Future Fuels Announces Closing of Brokered Offering for Gross Proceeds of C$6.6 Million
Published on 10/22/2026 at 14:30, 19 hours 32 minutes ago Unusual Machines Receives $16.9 Million Purchase Order from Powerus for American-Made Drone Components
Published on 10/23/2026 at 09:00, 1 hour 1 minute ago Municipality Finance issues a USD 135 million tap under its MTN programme
Published on 10/23/2026 at 09:00, 1 hour 1 minute ago Original-Research: THE NAGA GROUP AG (von NuWays AG): BUY
Published on 10/23/2026 at 07:00, 3 hours 2 minutes ago EQS-Adhoc: BB Biotech AG publishes its interim report
Published on 10/22/2026 at 18:00, 16 hours 2 minutes ago THERMADOR GROUPE : Completion of the share buy-back programme launched in August
Published on 10/22/2026 at 18:00, 16 hours 2 minutes ago bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics
Published on 10/22/2026 at 18:00, 16 hours 2 minutes ago H1 2026: marked improvement in operating results
Published on 10/22/2026 at 17:47, 16 hours 14 minutes ago Aéroports de Paris SA - 2026 9-month revenue